Glucose Uptake Accurately Assesses Tumor Response

Method more accurate than tumor size in study

MONDAY, Feb. 4 (HealthDay News) -- Analysis of glucose uptake in soft-tissue sarcomas by positron emission tomography is more accurate in assessing histopathologic response to treatment than tumor size, according to study results published in the February issue of Clinical Cancer Research.

Vladimir Evilevitch, M.D., Ph.D., from the University of Freiburg in Germany, and colleagues performed positron emission tomography with F18-fluorodeoxyglucose (FDG-PET) before and after adjuvant therapy to evaluate histopathologic response in 42 patients with soft-tissue sarcomas. A response was defined as at least 95 percent tumor necrosis.

The researchers found a significantly higher reduction in tumor FDG uptake among the 19 percent of patients who responded, while tumor size had no significant effect. Using a 60 percent reduction in FDG uptake as a threshold, assessment of histopathologic response had a sensitivity of 100 percent and a specificity of 71 percent, while tumor size had a sensitivity of 25 percent and a specificity of 100 percent.

"Quantitative FDG-PET was significantly more accurate than size-based criteria at assessing histopathologic response to neoadjuvant therapy," Evilevitch and colleagues conclude.

Full Text (subscription or payment may be required)

Physician's Briefing